Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.829 USD | +2.36% | -6.95% | +15.62% |
26/04 | VolitionRx Limited Announces Board Changes | CI |
23/04 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.62% | 68.07M | C | ||
-27.67% | 9.87B | A- | ||
-17.30% | 2.74B | C | ||
-11.15% | 2.24B | - | B- | |
-22.32% | 1.63B | C+ | ||
+59.69% | 1.39B | B- | ||
+23.58% | 772M | C- | ||
-1.31% | 760M | C+ | ||
-28.57% | 516M | C- | ||
+5.37% | 310M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VNRX Stock
- Ratings VolitionRx Limited